Platform Technology for Viral Vaccine Production: Comparison Between Attached and Suspension Vero Cells

  • Yvonne E. Thomassen
  • Gerco van Eikenhorst
  • Leo A. van der Pol
  • Wilfried A.M. Bakker
Conference paper
Part of the ESACT Proceedings book series (ESACT, volume 5)


Vero cells can be used as host for the production of many different types of viruses. The standard Vero culturing process consists of growing Vero cells adherent to microcarriers. Due to surface limitation the cells will have to be transferred to new microcarriers regularly. This subculturing of the cells, especially at large scale, is a complicated technique. This drawback can be overcome by using single cell suspension cultures. Vero cells growing in single cell suspension (sVero) were compared to adherent growing Vero cells (aVero) for their capability of producing polio virus. Using flow cytometry it was determined that sVero cells contained the polio virus receptor and were able to produce polio virus. These results indicate that sVero cells may be an ideal candidate for a platform based viral vaccine production approach. The combination of sVero cells with the flexibility of disposable bioreactors completes their suitability for these purposes.


Vero Cell Single Cell Suspension Stir Tank Reactor Virus Culture Spinner Flask 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank Guillermina Forno from Zelltek S.A. and Marina Etcheverrigaray from the Universidad Nacional del Litoral, Argentina for providing the sVero cells.


  1. Barrett PN, Mundt W, Kistner O, Howard MK. 2009. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 8:607–618.PubMedCrossRefGoogle Scholar
  2. Kersten G, Hazendonk T, Beuvery C. 1999. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17:2059–2066.PubMedCrossRefGoogle Scholar
  3. Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner FG, Barrett PN. 2007. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25:6028–6036.PubMedCrossRefGoogle Scholar
  4. Mendelsohn CL, Wimmer E, Racaniello VR. 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855–865.PubMedCrossRefGoogle Scholar
  5. Montagnon BJ, Fanget B, Nicolas AJ. 1981. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev Biol Stand 47:55–64.PubMedGoogle Scholar
  6. Oda T, Ohka S, Nomoto A. 2004. Ligand stimulation of CD155alpha inhibits cell adhesion and enhances cell migration in fibroblasts. Biochem Biophys Res Commun 319:1253–1264.PubMedCrossRefGoogle Scholar
  7. Paillet C, Forno G, Kratje R, Etcheverrigaray M. 2009. Suspension-Vero cell cultures as a platform for viral vaccine production. Vaccine 27:6464–6467.PubMedCrossRefGoogle Scholar
  8. van Wezel AL. 1967. Growth of cell-strains and primary cells on micro-carriers in homogeneous culture. Nature 216:64–65.PubMedCrossRefGoogle Scholar
  9. van Wezel AL, van Herwaarden JA, van de Heuvel-de Rijk EW. 1979. Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines. Dev Biol Stand 42:65–69.PubMedGoogle Scholar
  10. World Health Organization. 1998. Requirements for the use of animal cells as in vitro substrates for the production of biologicals.WHO Technical Report Series. pp 20–53.Google Scholar
  11. Zhang P, Mueller S, Morais MC, Bator CM, Bowman VD, Hafenstein S, Wimmer E, Rossmann MG. 2008. Crystal structure of CD155 and electron microscopic studies of its complexes with polioviruses. Proc Natl Acad Sci 105:18284–18289.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Yvonne E. Thomassen
    • 1
  • Gerco van Eikenhorst
    • 1
  • Leo A. van der Pol
    • 1
  • Wilfried A.M. Bakker
    • 1
  1. 1.National Institute for Public Health and the Environment (RIVM)BilthovenThe Netherlands

Personalised recommendations